New revision of Team-NB Position Paper on European AI Act
New revision of Team-NB Position Paper on European AI Act
Regulatory Affairs Medical Devices In Vitro Diagnostics
Wednesday, 23 April 2025
Kirsten Van Garsse, Authorized Representative Director & Regulatory Affairs Manager IVD
Share
\
\
X (Twitter) 
\
\
LinkedIn 
\
\
WhatsApp 
\
\
Copy link 
\
\
Mail
On April 14th, 2025, Team-NB, the European Association of Medical Devices Notified Bodies, released a revision of their Position Paper on the European Artificial Intelligence (AI) Act in relation to Regulation (EU) 2017/745 (MDR) and Regulation (EU) 2017/746 (IVDR).
Play
New revision of Team-NB Position Paper on European AI Act | QbD Group
AI-generated audio
2:45
This Position Paper provides an overview of the Team-NB perspective on the challenges of the AI Act, with particular attention to its implementation in the certification of (in vitro diagnostic) medical devices.
What is new?
Version 2 of this Team-NB Position Paper is a full revision of Version 1 (October 2021) and supersedes the Team-NB Position Paper (December 2022) on the designation of notified bodies under the Artificial Intelligence Act.
The paper discusses the designation and oversight of notified bodies under the AI Act, and the possibility to make use of the existing software-related codes to include AI Act requirements for in vitro diagnostic (IVDs) and other medical devices (MDs). Team-NB expresses its concern that there may otherwise be a shortage of designated notified bodies when the AI Act becomes applicable for MDs and IVDs on 02 August 2027.
The paper stresses the importance of having a common understanding of AI Act definitions such as ‘AI system’, ‘safety component’, ‘substantial modification’, and ‘significant change’. Further, guidance and development of standards are requested to harmonize approaches and expectations on compliance with fundamental rights like privacy, data protection, non-discrimination, and human dignity. Further, Team-NB warns that AI Act and MDR/IVDR requirements for post-market surveillance and vigilance should not lead to duplication of administrative efforts or compartmentalisation of information. Finally, the paper foresees challenges for notified bodies to effectively conduct conformity assessments through GDPR-compliant access to manufacturers’ training and validation data sets and, if necessary, also to high-quality independent datasets for additional testing.
What does it mean to you?
This Team-NB AI Act Position Paperis important for all manufacturers that are developing AI-enabled IVDs or MDs. It provides insight into how notified bodies, designated under MDR/IVDR are preparing to continue certification of such devices under the AI Act and which, mainly administrative, challenges they see in the implementation of the AI Act in the certification process of MDs and IVDs.
Discover more expert content
Previous
Regulatory Affairs
5 Mar 2025
Call for expression of interest in coordinated assessment of clinical investigations/performance studies
This pilot will allow sponsors to submit a single application for pilot coordinated assessments,...
Regulatory Affairs
30 Sep 2025
Adoption of Decision 2025/1324 on expert panels in the field of medical devices
The new panel can provide scientific and clinical advice for devices intended for small patient...
Regulatory Affairs
11 Jul 2024
Publication of Amendments to Regulation (EU) 2024/1860
Regulation (EU) 2024/1860 as regards a gradual roll-out of Eudamed, the obligation to inform in...
Regulatory Affairs
23 Apr 2025
New Team-NB Position Paper Released on IVDR certification process
This Position Paper is a Team-NB consensus document describing the pre-application, application and...
Regulatory Affairs
17 Dec 2025
Proposal for a Regulation Amending MDR and IVDR
The proposal introduces wide-ranging changes across the device lifecycle. It focuses on ...
Regulatory Affairs
5 Mar 2025
Call for expression of interest in coordinated assessment of clinical investigations/performance studies
This pilot will allow sponsors to submit a single application for pilot coordinated assessments,...
Regulatory Affairs
30 Sep 2025
Adoption of Decision 2025/1324 on expert panels in the field of medical devices
The new panel can provide scientific and clinical advice for devices intended for small patient...
Regulatory Affairs
11 Jul 2024
Publication of Amendments to Regulation (EU) 2024/1860
Regulation (EU) 2024/1860 as regards a gradual roll-out of Eudamed, the obligation to inform in...
Regulatory Affairs
23 Apr 2025
New Team-NB Position Paper Released on IVDR certification process
This Position Paper is a Team-NB consensus document describing the pre-application, application and...
Regulatory Affairs
17 Dec 2025
Proposal for a Regulation Amending MDR and IVDR
The proposal introduces wide-ranging changes across the device lifecycle. It focuses on ...
Regulatory Affairs
5 Mar 2025
Call for expression of interest in coordinated assessment of clinical investigations/performance studies
This pilot will allow sponsors to submit a single application for pilot coordinated assessments,...
Regulatory Affairs
30 Sep 2025
Adoption of Decision 2025/1324 on expert panels in the field of medical devices
The new panel can provide scientific and clinical advice for devices intended for small patient...
Next
- 1
- 2
- 3
Stay ahead in life sciences
Keeping up with the fast-paced life sciences industry doesn’t have to be overwhelming.
Our newsletter delivers the latest insights, industry updates, and expert content directly to your inbox, helping you stay informed and make smarter decisions.
Twitter Widget Iframe